Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ganirelix. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 12/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.84 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganirelix SCHEMBL719978 | 1.00 | GNRHR (0.98) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL19712192 | 1.00 | GNRHR (0.98) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL20521061 | 0.99 | GNRHR (1.00) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL29402980 | 0.99 | GNRHR (1.00) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL29390389 | 0.95 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL13625244 | 0.95 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL13624942 | 0.95 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL4405389 | 0.94 | GNRHR (0.88) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL61985 | 0.94 | GNRHR (0.86) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL30729525 | 0.94 | GNRHR (0.86) | GNRHRDRD1OPRM1MRGPRX2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | PELLFICURE PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3191087-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20150238561-A1 | Compositions of GnRH related compounds and processes of preparation | NOVO NORDISK A/S (DK) | 2015-08-27 | — | — | US | disclosed |
| US-8999383-B2 | Compositions of GnRH related compounds and processes of preparation | MERRION RESEARCH III LIMITED (IE) | 2015-04-07 | — | — | US | disclosed |
| EP-2288369-B1 | COMPOSITIONS OF GNRH RELATED COMPOUNDS AND PROCESSES OF PREPARATION | MERRION RES III LTD (IE) | 2014-07-09 | — | — | EP | disclosed |
| US-20090280170-A1 | Compositions of GnRH related compounds and processes of preparation | MERRION RESEARCH III LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-20090280169-A1 | Compositions of peptides and processes of preparation thereof | MERRION RESEARCH III LIMITED | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238561-A1 | Compositions of GnRH related compounds and processes of preparation | GNRHR, LPXN, PGF | GNRHR 1/4885DRD1 2034/4885OPRM1 1980/4885 |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | GNRHR 296/4885DRD1 4763/4885OPRM1 3077/4885 |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | GNRHR 296/4885DRD1 4763/4885OPRM1 3077/4885 |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | DHPS, SRD5A2, SRD5A1 | GNRHR 2701/4885DRD1 1248/4885OPRM1 902/4885 |
| US-20090280170-A1 | Compositions of GnRH related compounds and processes of preparation | GNRHR, LPXN, PGF | GNRHR 1/4885DRD1 2034/4885OPRM1 1980/4885 |
| US-20090280169-A1 | Compositions of peptides and processes of preparation thereof | IAPP, VIP, CETP | GNRHR 2351/4885DRD1 3441/4885OPRM1 3508/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | GNRHR 296/4885DRD1 4763/4885OPRM1 3077/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | GNRHR 296/4885DRD1 4763/4885OPRM1 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.